HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Double-blind, cross-over, international multicentre investigation of two doses of indoprofen compared with ASA and placebo in rheumatoid arthritis.

Abstract
Indoprofen 600 mg or 1000 mg/day, ASA 3600 mg/day and placebo were administered in randomized sequences according to a multiple 4 x 4 latin square design, balancing the treatments, periods and residual effects. Each treatment lasted 7 days. A total of 98 patients suffering from classical or definite rheumatoid arthritis completed the study. Analysis of the effectiveness indicates that both doses of indoprofen and ASA are significantly more active than placebo; indoprofen 1000 mg/day was the treatment preferred in most of the cases. Both doses of indoprofen were better tolerated than ASA.
AuthorsG Kolarz
JournalEuropean journal of rheumatology and inflammation (Eur J Rheumatol Inflamm) Vol. 4 Issue 1 Pg. 53-9 ( 1981) ISSN: 0140-1610 [Print] England
PMID7042362 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Phenylpropionates
  • Placebos
  • Indoprofen
  • Aspirin
Topics
  • Adult
  • Aged
  • Arthritis, Rheumatoid (drug therapy)
  • Aspirin (administration & dosage)
  • Clinical Trials as Topic
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Female
  • Humans
  • Indoprofen (administration & dosage)
  • Male
  • Middle Aged
  • Phenylpropionates (administration & dosage)
  • Placebos
  • Random Allocation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: